Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
Taiho Oncology, Inc.
Taiho Oncology, Inc.
Immunitas Therapeutics
Incyte Corporation
Intensity Therapeutics, Inc.
RAPT Therapeutics, Inc.
Icahn School of Medicine at Mount Sinai
Incyte Corporation